ArticleJournal of child and adolescent psychopharmacology2011
Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa.
Article in Journal of child and adolescent psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta-analysis.Brain and behavior · 2022Pooled it
- A Meta-Analysis of Dropout and Metabolic Effects of Antipsychotics in Anorexia Nervosa.Frontiers in psychiatry · 2020Pooled it
- Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2018Pooled it
- The safety of olanzapine in young children: a systematic review and meta-analysis.Drug safety · 2014Pooled it
- Double-blind placebo-controlled trial of quetiapine in anorexia nervosa.European eating disorders review : the journal of the Eating Disorders Association · 2012Trial
- Effect of psychopharmacological combinations on psychopathological symptom burden and BMI trajectories in patients with eating disorders.Frontiers in psychiatry · 2026Article
- Lurasidone and Fluvoxamine Combination in Eating Disorders with Comorbid Obsessive-Compulsive Disorder: Preliminary Evidence from an Observational Study.Medical sciences (Basel, Switzerland) · 2025Observational
- Use of atypical antipsychotics in individuals with anorexia nervosa.The mental health clinician · 2025Article
- Olanzapine use for the treatment of adolescents with anorexia nervosa - reflecting on research and clinical practice.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2024Article
- Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents.Journal of eating disorders · 2023Article
- Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review.Journal of eating disorders · 2023Review
- Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.PloS one · 2023Article
- Antipsychotics in the Treatment of Children and Adolescents with Anorexia Nervosa: A Systematic Review.Biomedicines · 2022Review
- Distinguishing delusional beliefs from overvalued ideas in Anorexia Nervosa: An exploratory pilot study.Journal of eating disorders · 2022Article
- Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.Journal of fungi (Basel, Switzerland) · 2022Review
- From efficacy to effectiveness: child and adolescent eating disorder treatments in the real world (part 1)-treatment course and outcomes.Journal of eating disorders · 2022Article
- Timing of Psychopharmacological and Nutritional Interventions in the Inpatient Treatment of Anorexia Nervosa: An Observational Study.Brain sciences · 2021Article
- Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug?Expert opinion on pharmacotherapy · 2020Review
- Canadian practice guidelines for the treatment of children and adolescents with eating disorders.Journal of eating disorders · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine assessment and treatment profiles of adolescent patients with anorexia nervosa and eating disorder not otherwise specified who received olanzapine as compared with an untreated matched sample.
methodA retrospective, matched-groups comparison study was completed. Medical files of 86 female patients treated in the eating disorder program at the Children's Hospital of Eastern Ontario were examined. Patients treated with olanzapine were initially identified through chart review and then matched to a diagnosis, age, and, when possible, treatment group that served as the active comparator. Weight gain was examined in a sample of 22 inpatients.
resultsPatients treated with olanzapine displayed greater evidence of psychopathology and medical compromise at the time of first assessment compared with those not treated. Rate of weight gain was not statistically different between groups when olanzapine was started during inpatient admissions. Medication effect on eating disorder cognitions could not be assessed given the presence of multiple confounders relating to treatment. Notable side effects included sedation and dyslipidemia in 56% of patients.
conclusionsDespite our best attempts at matching olanzapine-treated subjects with a control sample, analysis revealed significant differences between groups, suggesting greater illness severity in those augmented with olanzapine. Given these inherent differences, we were unable to draw any firm conclusions regarding the potential efficacy of olanzapine. Factors associated with the prescription of adjunctive pharmacotherapy in this cohort appear to be linked to illness severity, acuity, and associated comorbidity. The observed side-effect profile indicates the need for more consistent predrug screening and for closer monitoring during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.